No material impact on operations or stock. Monitor for any unexpected changes in the transition timeline or additional executive departures before February 2027, but this filing is a non-event for traders.
TVTX drugs
TVTX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 17 $54.14entry
- T+1 · 5mo ago +1.87%α +1.09% · $55.15
- T+5 · 5mo ago +6.56%α +7.60% · $57.69
- T+20 · 4mo ago +2.11%α +0.79% · $55.28
- T+60 · 2mo ago +22.22%α +19.07% · $66.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Travere Therapeutics disclosed the planned retirement of Chief Research Officer William Rote, effective February 17, 2027, with an orderly transition to Jula Inrig, who becomes EVP, Head of R&D and CMO effective July 1, 2026. This is a routine executive succession with long notice and a named internal successor, carrying no immediate financial or operational implications.
Key Facts
- Chief Research Officer William Rote, Ph.D., notified the company of his retirement effective February 17, 2027, the 10-year anniversary of his employment.
- Dr. Rote will continue in his current role through the retirement date and assist in the transition.
- Jula Inrig, M.D., current Chief Medical Officer, will assume Dr. Rote's responsibilities and be named Executive Vice President, Head of Research & Development and Chief Medical Officer effective July 1, 2026.
- The company expects to enter into a consulting arrangement with Dr. Rote post-retirement.
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001438533-26-000048 |
| Document: 0001438533-26-000048-index-headers.html | 0001438533-26-000048 |
| Document: 0001438533-26-000048-index.html | 0001438533-26-000048 |
| Document: 0001438533-26-000048.txt | 0001438533-26-000048 |
Track record
21 reports on TVTX
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
- Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
- Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
- Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Viewing Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
- Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers